Iowa City, IANCT07768345Now EnrollingIRB Ready

Respiratory Syncytial Virus (RSV) Clinical Trial in Iowa City, IA

Access cutting-edge respiratory syncytial virus (rsv) treatment through this phase 3 clinical trial at a research site in Iowa City. Study-provided care at no cost to qualified participants.

Sponsored by Pfizer

Quick Self-Assessment

See if you qualify for this Iowa City location

Preparing your pre-screening questions…

Expert Care in Iowa City

Access respiratory syncytial virus (rsv) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related respiratory syncytial virus (rsv) treatment provided free

Apply for This Iowa City Location

Check if you qualify for this respiratory syncytial virus (rsv) clinical trial in Iowa City, IA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Iowa City

    Convenient for IA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Iowa City site if eligible
  4. 4Begin participation

About This Respiratory Syncytial Virus (RSV) Study in Iowa City

The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised adults. This study is seeking participants who are 18 years of age and older and will be grouped based on prior RSV vaccination history. Participants are required to be immunocompromised per study protocol. All participants in this study will receive 1 shot to their arm of a RSVPreF vaccine. Participants will take part in this study for about 12 months and will need to visit the clinical study site at least 4 times.

Sponsor: Pfizer

Who Can Participate

Inclusion Criteria

Participants ≥18 years of age who are/were immunocompromised at the time of initial RSVpreF vaccination, per study protocol, and will be grouped based on prior RSV vaccination history:
Group 1 will include participants naïve to any RSV vaccine.
Group 2 will include participants who received a single prior dose of RSVpreF (Abrysvo) approximately 1 year (9 to 15 months) prior to enrollment.
Group 3 will include participants who received a single prior dose of RSVpreF (Abrysvo) approximately 2 years (21 to 27 months) prior to enrollment.
Group 4 will include participants who previously received 2 doses of RSVpreF in Study C3671023 Substudy B approximately 3 years (36 to 42 months) prior to enrollment.
Participants should have a life expectancy ≥12 months (365 days) in the opinion of the investigator at enrollment. Key

Exclusion Criteria

Prior history of any subtype of Guillain-Barré Syndrome (GBS) of any etiology.
History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any components of the study intervention(s).
Participants with a history of transplant rejection, or PTLD, or participants who have had treatment for these conditions, within 90 days prior to study enrollment or suspected chronic humoral or cellular rejection.
Receipt of B-cell depleting therapies within 180 days prior to initial study vaccination. Refer to the study contact for further eligibility details.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Iowa City?

Yes, this clinical trial (NCT07768345) has an active research site in Iowa City, IA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Respiratory Syncytial Virus (RSV) Treatment Options in Iowa City, IA

If you're searching for respiratory syncytial virus (rsv) treatment options in Iowa City, IA, this clinical trial (NCT07768345) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Iowa City research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced respiratory syncytial virus (rsv) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all respiratory syncytial virus (rsv) clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Iowa City, IA

See all rheumatoid arthritis clinical trials recruiting in Iowa City — not just this study.

Browse Rheumatoid Arthritis Trials in Iowa City →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsRSV TrialsAll Conditions →

Ready to Join in Iowa City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Iowa City, IA